Axogen, Inc. (LON:0HKD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.25B +91.2% |
| Revenue (ttm) | 159.73M +18.7% |
| Net Income | -1.56M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 75.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 565 |
| Average Volume | 1,729 |
| Open | 34.85 |
| Previous Close | 31.69 |
| Day's Range | 32.67 - 34.85 |
| 52-Week Range | 9.29 - 36.62 |
| Beta | 0.96 |
| RSI | 53.32 |
| Earnings Date | Feb 24, 2026 |
About Axogen
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc... [Read more]
Financial Performance
In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.
Financial numbers in USD Financial StatementsNews
Wasatch Micro Cap Fund Q4 2025 Performance Review
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and p...
Axogen Inc (AXGN) Trading Down 2.86% on Jan 28
Axogen Inc (AXGN) Trading Down 2.86% on Jan 28
Axogen Inc (AXGN) Trading 4.65% Higher on Jan 26
Axogen Inc (AXGN) Trading 4.65% Higher on Jan 26
Axogen Prices Upsized $124 Million Stock Offering
Axogen, Inc. (NASDAQ: AXGN) stock is trading lower on Thursday with a session volume of 1.92 million compared to the average volume of 885.013 thousand. Axogen’s 52-week stock range falls between $9....
Axogen Slips After Pricing $124M Upsized Share Offering
(RTTNews) - Axogen, Inc. (AXGN) announced that it has priced an upsized public offering of 4 million shares of its common stock at $31.00 per share.
Axogen (AXGN) Increases Stock Offering to $124 Million
Axogen (AXGN) Increases Stock Offering to $124 Million
Axogen (AXGN) Shares Decline After Upsized Public Offering
Axogen (AXGN) Shares Decline After Upsized Public Offering
Axogen stock dips after pricing $124M offering
Axogen (AXGN) stock drops on a $31 upsized 4M-share offering raising ~$124M.
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen announces proposed $85M public stock offering; shares down
Axogen (AXGN) plans an $85M stock offering with a $12.75M greenshoe to repay its Oberland loan and fund growth—read the details and implications.
Axogen Announces Proposed Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
AxoGen Inc at JPMorgan Healthcare Conference Transcript
AxoGen Inc at JPMorgan Healthcare Conference Transcript
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen CEO Axed 25,000 Shares From His Direct Holdings
The CEO of this innovative nerve regeneration company sold thousands of shares in December 2025, among multiple other insiders at the company who sold shares to close out that year.
Axogen sees Q4 net sales of up to $59.9M and FY2025 at $225.2M
Axogen (AXGN) previews Q4/FY25 revenue growth to $59.9M/$225.2M and 74%+ gross margin after FDA Avance BLA approval—see the key figures now.
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN)
Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN)
Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXGN)
Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXGN)
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Buy Rating | AXGN Stock News
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Buy Rating | AXGN Stock News
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Buy Rating | AXGN Stock News
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Buy Rating | AXGN Stock News
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment
FDA approves Axogen's Avance nerve graft for ... Full story available on Benzinga.com
FDA Approves Axogen's (AXGN) Avance for Nerve Repair
FDA Approves Axogen's (AXGN) Avance for Nerve Repair
Axogen gets FDA OK for Avance’s biologics license application
FDA Approves Axogen's AVANCE Nerve Allograft For Peripheral Nerve Repair
(RTTNews) - Axogen, Inc. (AXGN) announced that the U.S. Food and Drug Administration has approved the Biologics License Application (BLA) for AVANCE, an acellular nerve allograft (arwx).
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph...